946 related articles for article (PubMed ID: 21892840)
1. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
Tunis SL
Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
[TBL] [Abstract][Full Text] [Related]
2. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
Tunis SL; Willis WD; Foos V
Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
[TBL] [Abstract][Full Text] [Related]
3. Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US.
Tunis SL; Minshall ME
Curr Med Res Opin; 2010 Jan; 26(1):151-62. PubMed ID: 19919376
[TBL] [Abstract][Full Text] [Related]
4. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes.
Palmer AJ; Dinneen S; Gavin JR; Gray A; Herman WH; Karter AJ
Curr Med Res Opin; 2006 May; 22(5):861-72. PubMed ID: 16709308
[TBL] [Abstract][Full Text] [Related]
6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
[TBL] [Abstract][Full Text] [Related]
8. Impact of self-measurement of blood glucose on complications of type 2 diabetes: economic analysis from a Czech perspective.
Weber C; Kocher S; Neeser K; Bartaskova D
Curr Med Res Opin; 2010 Feb; 26(2):289-96. PubMed ID: 19947908
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.
Tunis SL; Sauriol L; Minshall ME
Appl Health Econ Health Policy; 2010; 8(4):267-80. PubMed ID: 20578781
[TBL] [Abstract][Full Text] [Related]
10. Self-monitoring of blood glucose in people with type 1 and type 2 diabetes living in France: the Entred study 2001.
Lecomte P; Romon I; Fosse S; Simon D; Fagot-Campagna A
Diabetes Metab; 2008 Jun; 34(3):219-26. PubMed ID: 18343703
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada.
Kobelt G; Andlin-Sobocki P; Maksymowych WP
J Rheumatol; 2006 Apr; 33(4):732-40. PubMed ID: 16583476
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
[TBL] [Abstract][Full Text] [Related]
13. Is self-monitoring of blood glucose appropriate for all type 2 diabetic patients? The Fremantle Diabetes Study.
Davis WA; Bruce DG; Davis TM
Diabetes Care; 2006 Aug; 29(8):1764-70. PubMed ID: 16873777
[TBL] [Abstract][Full Text] [Related]
14. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin.
Malanda UL; Welschen LM; Riphagen II; Dekker JM; Nijpels G; Bot SD
Cochrane Database Syst Rev; 2012 Jan; 1():CD005060. PubMed ID: 22258959
[TBL] [Abstract][Full Text] [Related]
15. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia.
Cohen N; Minshall ME; Sharon-Nash L; Zakrzewska K; Valentine WJ; Palmer AJ
Pharmacoeconomics; 2007; 25(10):881-97. PubMed ID: 17887808
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
Gao L; Zhao FL; Li SC
Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
[TBL] [Abstract][Full Text] [Related]
17. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
Palmer AJ; Tucker DM
Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
[TBL] [Abstract][Full Text] [Related]
18. Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the united states.
Tunis SL; Minshall ME
Am J Manag Care; 2008 Mar; 14(3):131-40. PubMed ID: 18333705
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.
Ridderstråle M; Jensen MM; Gjesing RP; Niskanen L
J Med Econ; 2013; 16(4):468-78. PubMed ID: 23384160
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]